- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
MPNs | Clinical
Key Considerations for Assessing Risk and Treating Myelofibrosis
July 31, 2022
Raajit Rampal, MD, PhD, discusses his recommended approach to assessing and treating patients with myelofibrosis.
Unmet Needs Remain in Treating Post-MPN Acute Leukemia
July 16, 2022
Gabriela Hobbs, MD, discusses the unmet needs that have yet to be filled in the post-myeloproliferative neoplasm acute leukemia space.
Momelotinib Shows Promise for the Future of Treating Myelofibrosis
July 15, 2022
In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, discussed phase 3 MOMENTUM study and how it has impacted the clinical trial development of momelotinib for the treatment of patients with myelofibrosis.
Rizzieri Considers Prognostic Models and Trial Data for Myelofibrosis
July 07, 2022
During a case-based roundtable event, David A. Rizzieri, MD, discussed the case of a 68-year-old patient with myelofibrosis.
Rusfertide May Reduce Need for Therapeutic Phlebotomy in Polycythemia Vera
June 30, 2022
Yelena Ginzburg, MD, discusses a long-term goal of the use of rusfertide in patients with chronic polycythemia vera.
Ruxolitinib Shows Superiority Over BAT in Second-Line, Inadequately-Controlled Polycythemia Vera
June 29, 2022
Five-year data from the RESPONSE-2 study combined with prior RESPONSE study results show that there is an option for the roughly 40% of patients with polycythemia vera who become intolerant or resistant to hydroxyurea.
NDA for Momelotinib Submitted to the FDA for Myelofibrosis
June 17, 2022
The FDA has received a new drug application for momelotinib as treatment of patients with myelofibrosis.
Recent Advances Provide More Options for the Treatment of Myelofibrosis
June 16, 2022
In an interview with Targeted Oncology, Raajit Rampal, MD, PhD, discussed the recent advances in myelofibrosis and what his hopes are for the future of this space.
MOMENTUM Aims to Complete Development of Momelotinib for Myelofibrosis Treatment
June 16, 2022
Aaron T. Gerds, MD, MS, discusses the clinical trial development of momelotinib, a JAK1/JAK2 inhibitor that is being investigated for the treatment of patients with myelofibrosis.
Pacritinib Displays Safety Profile Similar to Best Available Therapy in Myelofibrosis
June 04, 2022
An analysis presented during the 2022 ASCO Annual Meeting reveals that pacritinib's safety profile is comparable with beast available therapy, including ruxolitinib.